In this drug-target MR analysis, we assessed the effects of LLDs on lung cancer risk via six LLD targets (APOB, APOC3, HMGCR, LPL, NPC1L1, and PCSK9), comprising 12 lipid-lowering pathways. Here, NPC1L1 is linked to lung carcinoma.